Investors have sourced on publicly traded biotech companies in a big way. IPOs appear to be a less and less appealing way to cash out venture players. And don't look for any kind of a change near-term.
That bleak message has just been repeated for readers of the Financial Times, who were treated to a series of negative assessments from some of the U.K.'s top biotech execs. Too many trial disappointments in too short a period of time has been fingered for much of the blame.
One sample of the industry's view: "While there are some very strong companies developing--including Oxford BioMedica, Acambis and Protherics--the sector is really in dire shape," says Glyn Edwards, chief executive of Antisoma.
- read the article in the Financial Times